Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 3 Phase 1 3 Phase EARLY_PHASE1 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 74 Carcinoma, Non-Small-Cell Lung 73 Breast Neoplasms 39 Lung Neoplasms 31 Urinary Bladder Neoplasms 28 Nasopharyngeal Carcinoma 28 Ovarian Neoplasms 25 Neoplasm Metastasis 21 Cholangiocarcinoma 18 Triple Negative Breast Neoplasms 16 Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 13 Gallbladder Neoplasms 13 Biliary Tract Neoplasms 13 Uterine Cervical Neoplasms 12 Recurrence 12 Carcinoma, Transitional Cell 12 Nasopharyngeal Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Fallopian Tube Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 9 Lymphoma 7 Carcinoma 7 Bile Duct Neoplasms 7 Lymphoma, Non-Hodgkin 6 Adenocarcinoma 6 Carcinoma, Hepatocellular 5 Adenocarcinoma of Lung 5 Neoplasms by Site 4 Urothelial Cancer 3

Interventions

Rituximab 14 pirtobrutinib 6 ibrutinib 4 Vincristine 4 Doxorubicin 4 Prednisone 3 Cytarabine 3 Cyclophosphamide 3 zanubrutinib 2 acalabrutinib 2 Methotrexate 2 Etoposide 2 Bendamustine Hydrochloride 2 venetoclax 1 tositumomab I-131 1 idelalisib 1 ibritumomab tiuxetan 1 etoposide phosphate 1 entecavir 1 cirmtuzumab 1 axicabtagene ciloleucel 1 VAP-cyclo protocol 1 Tenofovir 1 Radiotherapy 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Everolimus 1 Drug Therapy 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Gemcitabine × Clear all

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡